An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma - Wikidata - wikimedia - TriplyDB

An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma

An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma

http://www.wikidata.org/entity/Q34926232

about

The Quest for Targets Executing MYC-Dependent Cell Transformation Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer Identification of therapeutic targets applicable to clinical strategies in ovarian cancer Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma.Drug Discovery Targeting Bromodomain-Containing Protein 4.Epigenetic Strategies to Boost Cancer Immunotherapies.BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.Concomitant BET and MAPK blockade for effective treatment of ovarian cancer.RNAi screens identify CHD4 as an essential gene in breast cancer growth.Amplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing.The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.Amplification of the NSD3-BRD4-CHD8 pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin.The kinome 'at large' in cancer.BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.Waste disposal-An attractive strategy for cancer therapy.BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1).Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy.Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage.JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer.Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.BRD4 facilitates replication stress-induced DNA damage response.The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.Small Cell Carcinomas of the Uterine Cervix and Lung: Proteomics Reveals Similar Protein Expression Profiles

P2860

Q26744579-A1EB0A34-8133-4D5E-805D-4D08F0C464AA Q26780387-4013BFF0-7E00-4C61-A44A-A7906C371901 Q28829029-1C05899E-DFA6-4BF4-9477-5B2C8730F935 Q30008980-B59D7659-AE2E-448A-ABB5-05A5356D29F0 Q30352390-1050C462-2D53-4F7A-8D0E-DB527DC0F6DB Q33838340-C0702928-789D-424C-9261-0A0648386CCD Q34047394-F3411BCA-7D62-4F50-9F75-48AC8DD1D2F3 Q34478968-4F93CAA2-A6C5-488A-B4D2-0E58DA9D2ADE Q34479551-7500EA7E-1549-4A1C-AA1B-BD2B5D081637 Q35843618-34A8D965-075F-4A5C-8EB0-954B94D97E23 Q36173845-E7F3ED96-D60D-4920-96B8-073589EC399D Q36341198-6D353099-FF57-4E8D-AFD3-8A4CCD2EE4F7 Q36510858-0343C712-1508-48C7-B5D1-7134894AC9D0 Q36540974-83FE2F2A-9035-4DF1-A42B-E20EE3631E84 Q36642197-A3489A2A-60DA-41FA-A2E6-F591BC2C1C28 Q36918007-F8A93726-F1EB-497F-BDB9-8995144F6220 Q37161750-3DA42BB3-A7FB-4607-9EB8-6554EEB4F9C7 Q37295618-299F9B8C-AA01-48E9-B366-3F3F4FD9FE94 Q37536618-7A54922D-DE2E-4C50-8AB5-C608474F37EB Q38637914-1D7BA20B-4B09-4196-B2C7-0398FFEC8522 Q38715428-75BF5A29-6067-45AE-BAB1-0EE042A3E497 Q38734234-73E10F77-24CD-40BC-96E2-859AF05FC59E Q38743421-DD89774F-E8DD-4382-9312-50D3FA91DAE9 Q38743834-696C5487-C77B-4683-B07E-70A3F78A5B77 Q38895410-718E4C40-8538-47EA-8C76-F57DE783EA3E Q39182849-E6990C13-0917-42F7-A295-EDA64BF2837A Q41612803-4681C151-1B7F-4F85-B411-7BD6ED0E6C56 Q42032794-63259C04-51B8-4D72-95C0-4EC6FE692956 Q42382162-4192FE1A-2EA5-44A6-BDA0-613C6C6342B9 Q42496540-2FCA63B6-3565-46CD-899A-43B0A2DEE9B2 Q44268034-A40021B6-1009-48B3-B86D-75DD32CC7FF2 Q47359072-E6E819A4-3DAB-4035-B8F3-C6446E5640F6 Q48023755-059D016F-44B2-40E5-AEBC-2F4C0944D21E Q48244721-F5E9AE65-FC7B-4619-9B93-F4B85DF3018F Q52595313-39F56AC2-554F-4318-82A7-B6C39729E19A Q52642120-051A715B-F791-41D8-8944-709EFF639AEA Q57791776-11400E16-A70B-4F78-8401-184E9DE77ED4

P2860

An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma

http://www.wikidata.org/entity/Q34926232

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

An in-tumor genetic screen rev ...... ic target in ovarian carcinoma

@ast

An in-tumor genetic screen rev ...... ic target in ovarian carcinoma

@en

An in-tumor genetic screen rev ...... ic target in ovarian carcinoma

@nl

type

label

An in-tumor genetic screen rev ...... ic target in ovarian carcinoma

@ast

An in-tumor genetic screen rev ...... ic target in ovarian carcinoma

@en

An in-tumor genetic screen rev ...... ic target in ovarian carcinoma

@nl

prefLabel

An in-tumor genetic screen rev ...... ic target in ovarian carcinoma

@ast

An in-tumor genetic screen rev ...... ic target in ovarian carcinoma

@en

An in-tumor genetic screen rev ...... ic target in ovarian carcinoma

@nl

P1433

Q34926232-131D1814-DCA2-4017-9DB3-568E46606A82

P1476

Q34926232-C626704C-89B0-4D69-9CE5-2F3D496EA871

P2093

Q34926232-0620E59C-0CE3-41F5-96D1-81E83C20072E

Q34926232-09CE2B1D-B801-45B8-A46B-59997E1B3ACA

Q34926232-0AB3F53C-5F6A-4B5D-8F69-0AF4B7FF6771

Q34926232-44D53131-0375-4578-845D-ACFFC1F69481

Q34926232-5F45A0A1-B155-4BFD-88AA-37B4F6EF296C

Q34926232-60D442D6-69E5-4D27-952D-3848678227E1

Q34926232-96513AD2-78C0-4038-A498-361FF33891CD

Q34926232-B650AFC6-3FE2-4B77-B40E-B58778C27715

Q34926232-BE422F28-CE4C-42E0-9C6F-C74B33C0FF08

Q34926232-C5AC9431-5073-48DD-88D2-5074D1FDB9D6

P2860

Q34926232-007B4586-4874-4FCE-97EB-46CF47FB92B9

Q34926232-0AD02EBA-BCCE-485A-BD42-7C78C647CD24

Q34926232-16B282CD-CC7A-497D-95DB-C26B1C226B1E

Q34926232-19097E33-4542-452C-B34E-D00011582F58

Q34926232-1CEAEF9D-E093-48D0-B4F7-27401E0ECC3C

Q34926232-1E764825-7E2B-45F3-8FC9-5987FDD0E571

Q34926232-21CE694A-6F0B-466B-B5BA-55150CD7E0EB

Q34926232-3602BD5B-C483-42AE-B5BC-6B51BBD1858D

Q34926232-3C172CD8-7F98-4C56-BF79-2E7321367D33

Q34926232-3FC34F9A-B44B-4D45-9927-EEFA6C90D22D

P304

Q34926232-4CCF418F-AF93-48CF-BCCF-0E4AC8AAD730

P31

Q34926232-00FCFE9D-9530-4322-A017-6D0A1D931E44

P356

Q34926232-9FA6CA59-B5E1-486E-A726-4B7FB5926A5C

P407

Q34926232-D19D656E-CAF6-4A13-B1F2-898B93722FA4

P433

Q34926232-95D77E24-32CE-405C-8BCD-CAAA82F0EC95

P478

Q34926232-1BC40511-E370-40B1-9F22-C8C00C66319E

P50

Q34926232-6D81D8A8-51B6-4756-A915-937872E46FB9

Q34926232-DFD67978-BBB3-4C59-A947-B040F56C7463

P577

Q34926232-9FCA5C3E-1447-4217-9881-412876B31E84

P5875

Q34926232-A2A7733F-3C33-4A61-8FC6-B13EAAA9F60F

P698

Q34926232-DAFEA8BB-1F67-4E55-BE36-73BBF1153B1D

P932

Q34926232-B3BBB8C5-5000-41CA-939E-B8D7E8EEDCEE

P356

PNAS.1422165112

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

An in-tumor genetic screen rev ...... ic target in ovarian carcinoma

@en

P2093

Anna C Schinzel

http://www.w3.org/2001/XMLSchema#string

Christian Bowman-Colin

http://www.w3.org/2001/XMLSchema#string

David M Livingston

http://www.w3.org/2001/XMLSchema#string

Huiying Piao

http://www.w3.org/2001/XMLSchema#string

James E Bradner

http://www.w3.org/2001/XMLSchema#string

Jennifer Curtis

http://www.w3.org/2001/XMLSchema#string

Jennifer Kutt

http://www.w3.org/2001/XMLSchema#string

Joyce F Liu

http://www.w3.org/2001/XMLSchema#string

Laura C Wong

http://www.w3.org/2001/XMLSchema#string

Maria Giuseppina Baratta

http://www.w3.org/2001/XMLSchema#string

P2860

p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors

Selective inhibition of BET bromodomains

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells

Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting

Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models

Integrated genomic analyses of ovarian carcinoma

High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

P304

232-237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1422165112

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270005589

http://www.w3.org/2001/XMLSchema#string

P698

25535366

http://www.w3.org/2001/XMLSchema#string

P932

4291641

http://www.w3.org/2001/XMLSchema#string